|Description||Pioneering messenger RNA therapeutics.|
|Venture Round, 12/2012 |
|Grant, 10/2013 ||$24.6M|
|Private Equity, 11/2013 |
|Venture Round, 1/2014 |
Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions.
Moderna has developed a broad intellectual property estate including more than 250 patent applications covering novel nucleotide chemistries and drug compositions. The company plans to develop and commercialize its innovative mRNA drugs through a combination of strategic relationships as well as new formed ventures.
Founded in late 2010 by Flagship VentureLabs, Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca and Alexion Pharmaceuticals.
The Science Behind Moderna: Messenger RNA Therapeutics™Added: 2/4/14
Moderna Featured in “Making a Difference in Health Care” by Harvard Business SchoolAdded: 2/4/14
What if mRNA Could Be a Drug? Moderna CEO Stephane Bancel at TEDxBeaconStreetAdded: 2/4/14